OS Therapies Inc OSTX
OS Therapies Inc (NYSE: OSTX) is an oncology drug developer. Its lead program, OST-HER2 (OST31-164), is in Phase 2 for Recurrent, fully resected pulmonary metastatic osteosarcoma. Its next catalyst on record is OST-HER2: Submit clinical module of BLA after Type B meeting with FDA (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: OST-HER2 — Submit clinical module of BLA after Type B meeting with FDA (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| OST-HER2 (OST31-164) | Recurrent resected pulmonary metastatic osteosarcoma (Phase IIb complete, fully enrolled; rolling BLA/conditional MAA in progress) | vaccine | Phase 2 |
| OST-tADC (tunable antibody-drug conjugate platform) | Solid tumors | antibody | Pre-clinical |
| ADXS-503 / ADXS-504 (Lm platform assets acquired from Ayala) | — | vaccine | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.